Preimplantation Genetic Testing Market 2030: Asia Pacific Leads Fastest Growth
The global preimplantation genetic testing market was valued at USD 852.4 million in 2024 and is projected to reach USD 1,282.1 million by 2030, registering a CAGR of 7.1% from 2025 to 2030. Rising cases of single-gene, mitochondrial, and other genetic disorders are supporting the increasing demand for preimplantation diagnosis and screening procedures. According to the Florida Department of Health, roughly one in every 33 babies in the U.S. is born with a congenital disability, affecting nearly 120,000 infants annually, further emphasizing the need for advanced genetic screening technologies. With the introduction of new testing solutions, demand is expected to grow steadily. For example, in July 2023, Thermo Fisher Scientific Inc. introduced two NGS-based tests for preimplantation genetic testing-aneuploidy (PGT-A), a widely used technique in assisted reproductive technology (ART) to detect embryos with chromosomal abnormalities prior to transfer. Traditional PGT-A requires embryo ...